Diplomat Pharmacy,Inc. (NYSE:DPLO) Files An 8-K Results of Operations and Financial ConditionItem 2.02 Results of Operations and Financial Condition.
On February26, 2018, Diplomat Pharmacy,Inc. (the “Company”) publicly announced its financial results for the fourth quarter and year ended December31, 2017. A copy of the Company’s news release is attached hereto as Exhibit99.1 and is incorporated herein by reference. The information in this Item 2.02 and the attached exhibit shall not be deemed filed for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as shall be expressly stated by specific reference in such filing.
Item 9.01Financial Statements and Exhibits.
Company press release dated February26, 2018
Diplomat Pharmacy, Inc. ExhibitEX-99.1 2 a18-7045_1ex99d1.htm EX-99.1 Exhibit 99.1 Diplomat Announces 4th Quarter and 2017 Year End Financial Results; Provides 2018 Guidance 4th Quarter Revenue of $1,…To view the full exhibit click here About Diplomat Pharmacy,Inc. (NYSE:DPLO) Diplomat Pharmacy, Inc. operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialized infusion therapy, and various other serious and/or long-term conditions. The Company operates through specialty pharmacy services segment. The Company offers various services, such as specialty drug dispensing, retail specialty services, hospital and health system services, and hub services. Its specialty drug dispensing services include patient care coordination, clinical services, compliance and persistency programs, patient financial assistance, specialty pharmacy training/consulting (Diplomat University), benefits investigation, prior authorization and risk evaluation and medication strategy (REMS).